Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.
Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions.
复制标题
DOI：
10.1097/jto.0000000000000302
复制
发表时间：
2014-11
期刊：
影响因子：
--
通讯作者：
Rajan A
中科院分区：
文献类型：
--
作者：
Burotto M;Thomas A;Subramaniam D;Giaccone G;Rajan A
分子生物学和生物信息学的进展已经鉴定出许多可能与非小细胞肺癌（NSCLC）患者管理相关的潜在生物标志物。尽管与这些生物标志物相关的文献越来越多，但需要解决的主要问题包括结果的有效性和再现性。此外，为了准确解释现有文献，必须明确区分生物标志物的预后和预测价值。肺癌患者生物标志物发现的实际适用性包括鉴定最有可能从辅助治疗中获益的早期NSCLC患者。从生物标志物中收集的信息有可能帮助评估靶向治疗的作用，包括免疫治疗在新辅助和辅助治疗中的作用。基因特征的作用和使用较新的平台，如RNA，甲基化和蛋白质特征正在探索早期NSCLC患者。本文就生物标志物发现在早期非小细胞肺癌中的应用作一综述
Advances in molecular biology and bioinformatics have resulted in the identification of a number of potential biomarkers that could be relevant in the management of patients with non-small cell lung cancer (NSCLC). Although there is an increasing amount of literature related to these biomarkers, major issues need to be resolved including validity and reproducibility of results. Additionally, in order to interpret the existing literature accurately a clear distinction must be made between the prognostic and predictive value of biomarkers. The practical applicability of biomarker discovery for patients with lung cancer includes the identification of patients with early-stage NSCLC who are most likely to benefit from adjuvant therapy. Information gleaned from biomarkers has the potential to help in evaluating the role of targeted therapies including immunotherapy in the neoadjuvant and adjuvant setting. The role of gene signatures and the use of newer platforms such as RNA, methylation and protein signatures is being explored in patients with early stage NSCLC. This review focuses on the applications of biomarker discovery in patients with early stage NSCLC